Stoke Therapeutics Aligns with FDA on Zorevunersen NDA Pathway for…

Event summary

Stoke Therapeutics completed a successful FDA meeting to align on the planned U.S. NDA submission for zorevunersen, an investigational treatment for Dravet syndrome.
The FDA agreed to a multicomponent assessment of four Vineland-3 subdomains to evaluate changes in cognition and behavior in the Phase 3 EMPEROR study.
Stoke plans to submit data to the FDA in the first half of 2027 and complete the NDA submission in the second half of 2027, aiming for a potential U.S. approval and launch in early 2028.
The Phase 3 EMPEROR study is anticipated to read out data in the third quarter of 2027.

The big picture

Stoke Therapeutics' alignment with the FDA on the NDA pathway for zorevunersen marks a significant step forward in the development of a potential disease-modifying treatment for Dravet syndrome. The agreement on the multicomponent assessment of Vineland-3 data underscores the FDA's recognition of the severity of the condition and the need for innovative therapies. This development comes at a time when the biotechnology industry is increasingly focused on RNA medicine as a means to address genetic disorders. The strategic collaboration with Biogen further strengthens Stoke's position in the market, providing access to Biogen's global commercialization capabilities.

What we're watching

Regulatory Alignment: How the FDA's acceptance of the multicomponent assessment of Vineland-3 data will impact the NDA submission and potential approval timeline for zorevunersen.
Clinical Trial Execution: Whether the Phase 3 EMPEROR study will meet its primary and secondary endpoints, particularly the reduction in seizure frequency and improvements in cognition and behavior.
Market Dynamics: The pace at which Stoke Therapeutics can commercialize zorevunersen in the U.S. and potentially expand into other markets, given the strategic collaboration with Biogen.